Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/70875
Title: Efficacy and safety of clidinium/chlordiazepoxide as an add-on therapy in functional dyspepsia: A randomized, controlled, trial
Authors: Siripa Puasripun
Nithi Thinrungroj
Kanokwan Pinyopornpanish
Phuripong Kijdamrongthum
Apinya Leerapun
Taned Chitapanarux
Satawat Thongsawat
Ong Ard Praisontarangkul
Keywords: Medicine
Issue Date: 1-Apr-2020
Abstract: © 2020 The Korean Society of Neurogastroenterology and Motility Background/Aims The treatment of refractory functional dyspepsia (FD) is a challenge. Clidinium/chlordiazepoxide is a combination of antispasmodic and anxiolytic drugs that has been used as an adjunct treatment for FD in clinical practice with limited supporting evidence of efficacy. The aim of the study is to assess the efficacy and safety of clidinium/chlordiazepoxide as an adjunct treatment to a proton pump inhibitor (PPI) in refractory dyspepsia. Methods We performed a study of patients who met the Rome IV criteria for FD who failed to respond to PPIs. Patients were randomly assigned to groups that received clidinium/chlordiazepoxide or placebo as an add-on treatment to PPI for 4 weeks. The primary outcome was the rate of responders, which was defined as a > 50% reduction in dyspepsia symptom score after 4 weeks of treatment. The secondary outcomes were an improvement in the quality of life and the safety profile. Results Between March 2017 and February 2018, 78 patients were enrolled. The rates of responders in the clidinium/chlordiazepoxide group and placebo groups were 41.03 % and 5.13% at week 4 (P < 0.001). The clidinium/chlordiazepoxide group also showed significant improvement in overall quality of life over placebo. However, the clidinium/chlordiazepoxide group had more frequent drowsiness than the placebo group (30.27% vs 6.52%, P = 0.034). There were no major adverse events in either group. Conclusions Clidinium/chlordiazepoxide significantly improved dyspeptic symptoms and quality of life. This combination may be used as an add-on therapy in FD patients without major adverse events.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089557402&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/70875
ISSN: 20930887
20930879
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.